PMV PHARMACEUTICALS INC (PMVP)

Company Profile

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 62 full-time employees. The company went IPO on 2020-09-25. p53 is a tumor suppressor protein, guardian of the genome, and normal or wild type, p53 has the ability to eliminate cancer cells. The Company’s lead product candidate, PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53PC14586 has shown selective on-target activity, which primarily functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition (TGI), and tumor regression as a single agent. The firm has initiated a Phase I/II clinical trial for PC14586. In addition, it is also granted food and drug administration (FDA) Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

Company Info

PMV PHARMACEUTICALS INC

One Research Way

Princeton NEW JERSEY 08512

P: 16096426664

CEO: David H. Mack

Employees: 62

Website: https://www.pmvpharma.com/